PROFILE OF CD150 EXPRESSION IN BONE MARROW CELLS OF PATIENTS WITH ACUTE MYELOID LEUKEMIA

Area of Science:

• Hematology
• Oncology
• Immunophenotyping

Background:

• Acute Myeloid Leukemia (AML) is a heterogeneous cancer.
• Understanding molecular differences in AML subtypes is crucial for targeted therapies.
• CD150 cell surface expression in AML requires further investigation.

Purpose of the Study:

• To investigate the expression profile of CD150 on bone marrow cells in AML patients.
• To determine the association of CD150 expression with specific AML subtypes.
• To explore the potential role of CD150 as a diagnostic or prognostic marker in AML.

Main Methods:

• Analysis of bone marrow aspirates from 55 newly diagnosed AML patients.
• Utilizing flow cytometry to evaluate immunophenotype and CD150 expression.
• Categorization of AML subtypes into M1, M2, M3, and M5.

Main Results:

• CD150 expression was detected in 25.5% of AML cases, predominantly in the M3 subtype (AML M3).
• AML M3 cases showed significantly higher CD150 expression levels compared to non-M3 subtypes.
• CD150 expression in AML M3 was associated with specific immunophenotypic markers and negatively correlated with CD56.

Conclusions:

• High CD150 expression is a distinctive characteristic of AML M3, aiding in the identification of immature blast cells.
• CD150 may serve as an additional phenotypic marker for AML M3 diagnosis.
• The negative association with CD56 suggests CD150 may have prognostic value in AML patients.